Best Life Sciences Platforms and Tools Companies in Canada
The 258 best Life Sciences Platforms and Tools companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genizon BioSciences.
Canada's Life Sciences Platforms and Tools sector has 258 companies tracked, carrying $681M in total disclosed funding and zero unicorns, which tells you something honest about where this market sits right now: deep in build mode. The global tools market was valued at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027, a 10.8% CAGR driven by advances in quantitative accuracy, mass spectrometry resolution, and information sciences. EnGene leads our Canadian cohort at $54M raised, followed by Feldan at $40M. Regulatory challenges remain a real friction point, slowing commercialization timelines for platform companies that are otherwise technically ahead.
So what's the shape of the opportunity? I'd point you toward the mid-tier, where Future Fields ($14M) and ImmunoPrecise Antibodies ($18M) are competing on differentiated biology rather than scale. BDC and Sustainable Development Technology Canada are the most active backers here, which signals patient capital, not venture velocity. The Canadian cohort isn't chasing the Illumina or Danaher playbook yet. It's building the substrate, the tools, the platforms that larger acquirers eventually need, and at $681M cumulative disclosed funding across 258 companies, the average check size stays modest. The runway for consolidation looks long, but the underlying science doesn't.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Genizon BioSciences Genes and biomarkers discovery | $130M | 221 mo ago | — | Jan Mellegers Interim President & CEO | — | — | — |
| 2 | enGene Developer of oral non-viral gene therapy platform 50Patents top 28%Moat top 29%Funding top 30%Innovation top 38% All 9 signals ▾Patentstop 28% Moattop 29% Fundingtop 30% Innovationtop 38% Newstop 46% Growthtop 48% Marketbottom 46% Techbottom 45% Globalbottom 44% Patents: 174 patents matched (strict assignee match) · 40 filings since 2022 vs 69 in 2017-21 Moat: Editorial + unicorn rating 6/10 · IP moat: 174 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $54M | 19 mo ago | 57 | — | 12 signals ▼33% Earnings · Leadership · Announcements | 174 patents Chitosan nanoparticle gene delivery platforms for cancer immunotherapy and localized gene expression | 1 internship · 2 awards |
| 3 | Feldan Developing delivery system of proteins inside cells directly 29Funding top 33%Moat top 38%Tech bottom 46%Market bottom 38% All 5 signals ▾Fundingtop 33% Moattop 38% Techbottom 46% Marketbottom 38% Globalbottom 37% Funding: Raised $40.4M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $40M | 14 mo ago | 36 | — | — | — | — |
| 4 | iVexSol Developer of a platform for the production of vectors | $39M | 40 mo ago | 34 | Rodney Rietze Co-Founder & CEO | — | — | — |
| 5 | Nicoya Life Provider of hyperspectral optical microscopes for surface analysis | $35M | 54 mo ago | 105 | — | — | — | 2 launchs |
| 6 | Precision Nanosystems Manufactures instruments, kits, and reagents for nanomedicine development | $25M | 45 mo ago | 150 | — | — | — | — |
| 7 | Intellipharmaceutics International Specialty company developing generic controlled oral solid dosage drugs | $24M | 79 mo ago | 11 | Isa Odidi Chief Executive Officer | — | — | — |
| 8 | Therapure Biopharma Contract development and manufacturing organization that specializes in the development, manufacture of… | $24M | 129 mo ago | 225 | — | — | 52 patents Hemoglobin-targeted drug carriers and large‑scale protein/albumin purification technologies | — |
| 9 | ARTMS Provider and developer of radioisotope technologies | $22M | 63 mo ago | 34 | Charles Conroy CEO | — | — | — |
| 10 | Covalon Develops technologies, products and services to address the needs of medical device companies and healthcare… | $20M | 80 mo ago | 88 | Val DiTizio Co-Founder | — | — | 3 launchs |
| 11 | Lignol Innovations Provider of scientific research and publication services | $19M | 154 mo ago | — | Ross MacLachlan CEO & Chairman | — | — | — |
| 12 | ImmunoPrecise Antibodies CDMO focused on antibody discovery and pre-clinical services | $18M | 23 mo ago | 80 | Chris Buyse Board of Directors | 4 signals ▼56% Earnings · M&A | 5 patents Monoclonal antibody production and diagnostics for estrogen receptors and muscular dystrophy biomarkers | — |
| 13 | Mirexus Biotechnologies Safe & Natural polysaccharide based Nanomaterials | $17M | 102 mo ago | — | Phil Whiting President & CEO | — | — | — |
| 14 | Ceapro Developer of pharmaceutical and diagnostic products addressing unmet medical needs | $17M | 81 mo ago | 38 | Gilles Gagnon President & CEO | — | 63 patents Extraction, purification, and formulation of oat-derived beta‑glucan for nutraceutical and pharmaceutical applications | — |
| 15 | Future Fields Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins 37Moat top 37%Funding top 39%Patents top 44%Tech top 49% All 9 signals ▾Moattop 37% Fundingtop 39% Patentstop 44% Techtop 49% Talentbottom 49% Innovationbottom 46% Marketbottom 42% Globalbottom 40% Newsbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 7 patents Funding: Raised $13.6M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $14M | 12 mo ago | 40 | Matt Anderson-Baron Chief Executive Officer | — | 7 patents Insect-based recombinant protein biomanufacturing and engineered insect production of target compounds | 1 job opening · 1 launch |
| 16 | Stem Cell Technologies Developer of cell culture media and ancillary reagents for life science research | $12M | 62 mo ago | 129 | — | — | — | 1 award |
| 17 | Earth Alive Clean Technologies Biotech company addressing environmental challenges in agriculture, mining, and industry | $12M | 63 mo ago | 11 | David Gilmour CEO | — | — | 1 partnership |
| 18 | High Q Technologies Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis | $10M | 27 mo ago | 24 | Wendy Hinchey CEO | — | — | 1 job opening · 1 partnership |
| 19 | LightIntegra Technology Develops technology to detect microparticle content | $10M | 74 mo ago | 7 | — | — | — | — |
| 20 | Imaging Dynamics Company Develops imaging technology | $9M | 116 mo ago | 13 | — | — | 11 patents Advanced digital radiography: dual‑energy imaging, distortion correction, and noise reduction. | — |
| 21 | Lexaria Bioscience Developer of drug delivery technology designed to improve drug absorption | $8M | 32 mo ago | 6 | Chris Bunka CEO & Chairman | 3 signals ▼50% Earnings · Funding | — | 1 launch |
| 22 | CryoStasis Developer of subzero unfrozen cell preservation platform for cell and gene therapy | $8M | 34 mo ago | 8 | — | — | 10 patents Cryogenic preservation and storage systems for biological specimens and tissues | — |
| 23 | Axela Platforms for multiplex nucleic acid and protein analysis | $8M | 104 mo ago | 20 | M Cynthia Goh Founder | — | — | — |
| 24 | Insception Largest cord blood program in Canada | $7M | 164 mo ago | 57 | — | — | — | — |
| 25 | Microbix Developer of various biological products and technological solutions | $7M | 39 mo ago | 100 | — | — | — | — |
| 26 | DxNA Developer and manufacturer of high value molecular diagnostic instruments | $7M | 126 mo ago | 15 | — | — | — | — |
| 27 | BioIntelligence Technology Developer of intelligent monitoring instruments to enhance bioprocess development | $6M | 25 mo ago | 11 | — | — | — | 2 job openings |
| 28 | PanTHERA CryoSolutions Provider of a platform for cell cryopreservation | $6M | 64 mo ago | 10 | Jason Acker Co-Founder | — | — | — |
| 29 | Sequence Bio Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases… | $5M | 82 mo ago | 20 | Chris Gardner CEO & President | — | — | — |
| 30 | MedGenesis Therapeutix Therapeutics for neurological diseases | $5M | 173 mo ago | 4 | Erich Mohr Chairman and CEO | — | — | — |
| 31 | Somru Bioscience Developing antibody technology for research, diagnostic and therapeutic applications | $4M | 95 mo ago | 21 | Dihan Ahsan CEO & President | — | — | 1 partnership |
| 32 | DoseBiome Provider of prebiotic and probiotic products | $4M | — | 9 | Ted Jin Founder & CEO | — | — | — |
| 33 | Metabolomic Technologies Developer of metabolomics-based diagnostics | $4M | 79 mo ago | 11 | Richard Fedorak Founder | — | — | — |
| 34 | Saguaro Developer of 3D cell culture products for drug discovery | $4M | 24 mo ago | 8 | Felix Perusse Co-Founder | — | — | — |
| 35 | Prognomix Offers a diagnostic and predictive technology targeting Type 2 diabetes patients | $4M | 230 mo ago | — | Normand Balthazard ex-CEO | — | — | — |
| 36 | CelluForce Provides Cellulose NanoCrystals (CNC) solutions | $4M | 134 mo ago | 14 | — | — | — | 4 launchs |
| 37 | Interomex BioPharmaceuticals Yeast-based repressed transcription activator (RTA) platform to identify inhibitors of protein-protein… | $4M | 296 mo ago | — | Konstantine Sarafis Co-Founder | — | — | — |
| 38 | Acorn Provider of stem cell biobanking services | $3M | 28 mo ago | 19 | Patrick Pumputis Co-Founder & CSO | — | — | — |
| 39 | Aereus Technologies Copper alloy based coating for bacterial protection | $3M | 69 mo ago | 12 | — | — | — | — |
| 40 | Kinexus Provider of proteomics services for tracking protein kinases and other cell signaling proteins | $2M | 123 mo ago | — | Steven Pelech President | — | — | — |
| 41 | Nanovista Developing multimodal visualization agents | $2M | 100 mo ago | 3 | Jinzi Zheng Co-Founder | — | — | — |
| 42 | Actlabs Provider of analytical testing and development services for various industries. | $2M | 254 mo ago | 452 | Eric Hoffman Founder | — | — | 1 job opening |
| 43 | NeXtraction Operator of a biotechnology company providing extraction, purification, and formulation services | $2M | 66 mo ago | 9 | Mark S. Dolar CEO & President | — | — | — |
| 44 | Mesosil Developer of antimicrobial materials | $2M | 24 mo ago | 5 | — | — | 6 patents Controlled ion and metal‑oxide release systems for dental and medical therapeutics | — |
| 45 | VoxCell BioInnovation Manufacturer of 3D bioprinters | $1M | 15 mo ago | 15 | Andrew Garland Co-Founder & CTO | — | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 46 | Nanalysis Corp. Manufactures of benchtop NMR spectrometers 74Patents top 22%News top 24%Growth top 25%Innovation top 29% All 10 signals ▾Patentstop 22% Newstop 24% Growthtop 25% Innovationtop 29% Moattop 38% Markettop 39% Partnerstop 40% Fundingtop 46% Techtop 46% Globalbottom 49% Patents: 80 patents matched (strict assignee match) · 39 filings since 2022 vs 17 in 2017-21 News: 15 BI events in 12 mo (of 96 tracked, 9 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 74/100 | $1M | 5 mo ago | 107 | — | 15 signals ▲114% Earnings · Funding · Announcements | 80 patents Magnetic resonance hardware: magnet pole pieces, structures, and data acquisition systems. | — |
| 47 | Fusion Genomics Provider of molecular diagnostics and cloud-based analytic tools | $1M | 77 mo ago | 12 | Greg Stazyk Co Founder | — | — | — |
| 48 | Micromensio Developer of on-chip sensors for point-of-need diagnostics solution | $780K | 57 mo ago | 2 | Enver Kilinc Co-Founder & CTO | — | — | — |
| 49 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 15 mo ago | — | Dominique Cheneval President and Co-Founder | — | 21 patents Novel benzopyran therapeutics and mRNA‑stability screening assays for drug discovery | — |
| 50 | Entos Pharmaceuticals Provider of nanotech-based drug delivery solutions | $100K | 12 mo ago | 41 | — | — | 53 patents Oncolytic viral therapies and SARS‑CoV‑2 nucleic‑acid vaccine platforms | 1 partnership |
Top 12 Life Sciences Platforms and Tools companies in Canada
#1
Series B · Quebec City, Quebec · founded 2007 · 36 employees$40.4Mraised▾
Feldan is developing regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The company has developed Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments. The Shuttle can overcome obstacles faced by nucleic acid delivery for therapeutic use by decreasing the regulatory process and accelerating the translation of discoveries into clinical applications. The Shuttle also allows enables the development of in-house medical applications as well as in collaboration with partners.
- Apr 2025Series B—
- Feb 2025Series B—
- Sep 2024Series B$21M
- Jun 2023Series B$16.5M
#2
Series A · Edmonton, Alberta · founded 2017 · 40 employees$13.6Mraised▾
Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins. The company has developed a platform called EntoEngine that assists in the production of serum-free medical products. They also offer various products and services related to recombinant proteins.
- Jun 2025Series A$8M
- Feb 2023Seed$11.2M
- Feb 2021Seed$2.2M
- Aug 2020Seed$150K
#3
Public · Saint laurent, Quebec · founded 1999 · 57 employees$54Mraised▾
EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.
- Oct 2024Post IPO$43.4M
- Feb 2024Post IPO—
- Dec 2023Convertible Debt$22.5M
- Oct 2020Grant (prize money)—
#4
Public · Calgary, Alberta · founded 2009 · 107 employees$1Mraised▾
Manufactures of benchtop NMR spectrometers. The company develops and manufactures compact, portable, benchtop Magnetic Resonance Imaging and Spectroscopy products. The NMR instruments are used for teaching, biotech and pharma, polymer research, food science, synthetic chemistry, reaction monitoring/process analytical technology, mining and minerals, oil and gas, security and defense, cannabis, and more.
- Dec 2025Post IPO$1.8M
- Apr 2023Post IPO$2.2M
- Aug 2021Post IPO$1.4M
- Jun 2019Post IPO$1.5M
#5
Public · Victoria, British Columbia · founded 1989 · 80 employees$18.4Mraised▾
CDMO focused on antibody discovery and pre-clinical services
- Jul 2024Post IPO$2M
- Jul 2020Grant (prize money)—
- Apr 2020Post IPO$1.8M
- Apr 2020Grant (prize money)$75K
#6
Series A · Victoria, British Columbia · founded 2020 · 15 employees$1.3Mraised▾
Manufacturer of 3D bioprinters. It develops 3D bio-printers and bio-inks for drug development and tissue engineering. Its technology uses lasers that crosslink liquid polymers and bio-inks. It applies to the manufacturing of biomimetic tissues that reduce the time and cost of drug testing.
- Feb 2025Series A$1.7M
- Dec 2023Series A$1.5M
- Nov 2022Grant (prize money)—
- Aug 2022Seed$1.3M
#7
Funding Raised · Burnaby, British Columbia · founded 1999$625.5Kraised▾
Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform. The company is using its proprietary technology Quest to discover small molecules. The technology involves identification of mRNA stability regulatory elements (SCEs); cloning of the target SCE into a relevant diseased cell and then the production of stable cell line; screening of compound libraries.
- Mar 2025Grant (prize money)$625.5K
#8
Series A · Toronto, Ontario · founded 2018 · 34 employees$39Mraised▾
iVexSol is a manufacturer and developer of the vector. It offers its flagship intelligent transformative platform for developing lentiviral vector cell lines.
- Jan 2023Series A$23.8M
- Dec 2020Series A$13M
- Aug 2020Seed$250K
- Sep 2019Seed$2M
#9
Seed · Waterloo, Ontario · founded 2013 · 24 employees$10.2Mraised▾
Developer of quantum-enabled electron paramagnetic resonance systems for protein analysis. The company’s systems resolve complex problems in protein dynamics for drug discovery. It offers a sample measurement service to provide researchers with insights into molecular dynamics. The organization’s technology aims to redefine standards in protein structure determination.
- Feb 2024Seed$3.8M
- 2019Seed$6.5M
#10
Series A · Sherbrooke, Quebec · founded 2014 · 11 employees$6Mraised▾
BioIntelligence Technology is involved in developing intelligent monitoring instruments to accelerate bioprocess development for biotechnology industries. The instrument (Intelligent Inline Spectrometer) uses microorganisms or cells to biosynthesize a molecule or a group of molecules.
- Apr 2024Series A$5M
- Jan 2016Seed$1M
#11
Public · Kelowna, British Columbia · founded 2004 · 6 employees$8.3Mraised▾
Developer of drug delivery technology designed to improve drug absorption. The technology enhances the effectiveness of active pharmaceutical ingredients. It formulates therapeutics into oral formats like tablets and suspensions. The technology is available for licensing to improve existing or create new products.
- Oct 2023Post IPO$1.6M
- Dec 2021Post IPO$1.2M
- Jul 2020Post IPO$100K
- May 2020Post IPO$2M
#12
Seed · Quebec City, Quebec · founded 2020 · 8 employees$4.1Mraised▾
Developer of 3D cell culture products for drug discovery. The company is developing next-generation technologies for drug discovery and life-saving therapies. The company's product line inlcudes ChromaLive Non-Toxic Dyes, hydrogel for 3D cultures, and PrimaFeed defined culture medium.
- Jun 2024Seed$3M
- Feb 2022Seed$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Canada
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,804 Canada-affiliated papers.
- Ministry of Education187
- University of Toronto155
- University of British Columbia117
- McGill University108
- Ministry of Agriculture72
- Gene8→75
- Genome16→64
- Transcriptome2→41
- Immune system1→24
- Drug discovery2→21
- Microbiome1→19
- Gut flora1→18
- Metabolomics2→17
- Genome4→18
- Drug discovery1→10
- Disease2→55
- Clinical trial1→24
- Immune system1→19
- Gene1→19
- Epigenetics1→13
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.